Considering the inhibitory effect of Brd4 inhibition on CD8+ T cells function and differentiation, it could not be feasible to combine Brd4-targeting therapy with CAR-T-/TCR-T-based immunotherapy for incurable cancer. Here, CD8A is linked to cancer.